Other
Metastatic
0
Pipeline Programs↗
27
Active Trials↗
22
Companies Involved↗
Metastatic is an early-stage landscape with 0 programs across 22 companies. The most active players are Novartis, AstraZeneca, Lyvgen Biopharma Holdings Limited.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
115
clinical trials
Completed42 · 37%
Terminated26 · 23%
Unknown status14 · 12%
Recruiting12 · 10%
Active, not recruiting11 · 10%
Not yet recruiting4 · 3%
Other6 · 5%
Clinical Trials
Trial Activity
115 trials
Study of 111In-XYIMSR-01 SPECT/CT in Patients With Metastatic Clear Cell Renal Cell
Recruiting·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 1·NCT07062549·6 enrolled
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Recruiting·—·Phase 2·NCT06239220·25 enrolled
Vebreltinib for Advanced or Metastatic CCS
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT07153887·30 enrolled
Sacituzumab Govitecan Plus EV in Metastatic UC
Recruiting·—·Phase 1/2·NCT04724018·106 enrolled
TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC
Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT06236425·7 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)